check_circleStudy Completed
Breast Neoplasms, Breast Cancer, Metastatic
Bayer Identifier:
10654
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Evaluation of BAY59-8862 in Taxane-Resistant Metastatic Breast Cancer Patients
Trial purpose
Breast cancer is the most common form of cancer among women in developing countries, accounting for approximately one-fifth of all female cancers in the United States. Although mortality rates are declining in some countries, it remains the leading cause of death in women aged 40-55 years. The median survival for women with metastatic breast cancer is 2-3 years but there is significant variability in this population. The primary goals of treatment in patients with metastatic breast cancer are improvement or maintenance of quality of life and prolongation of survival. The taxanes, paclitaxel and docetaxel, were incorporated into the treatment of metastatic breast cancer in the 1990's. The usefulness of the taxanes is limited by the development of tumor resistance to these agents. This phase II trial with BAY59-8862 will be conducted to determine the anti-tumor efficacy of BAY59-8862 in taxane-resistant metastatic breast cancer.
Key Participants Requirements
Sex
FemaleAge
18 YearsTrial summary
Enrollment Goal
82Trial Dates
April 2002 - February 2004Phase
Phase 2Could I Receive a placebo
NoProducts
Cytotoxic Taxane (BAY59-8862)Accepts Healthy Volunteer
NoWhere to participate
Status | Institution | Location |
---|---|---|
Completed | Heraklion, 711 10, Greece | |
Completed | Jena, 07740, Germany | |
Completed | Stuttgart, 70376, Germany | |
Completed | London, SW3 6JJ, United Kingdom | |
Completed | Berlin, 10117, Germany | |
Completed | Haifa, 3109601, Israel | |
Completed | Biella, 13900, Italy | |
Completed | Parma, 43126, Italy | |
Completed | Aarau, 5001, Switzerland | |
Completed | London, NW3 2QG, United Kingdom | |
Completed | Ashkelon, 7830604, Israel | |
Completed | Forlì, 47100, Italy | |
Completed | Warszawa, 04-141, Poland | |
Completed | Maroussi, 15123, Greece | |
Completed | Milano, 20089, Italy | |
Completed | Olsztyn, 10-228, Poland | |
Completed | Ramat Gan, 52482, Israel | |
Completed | Bergamo, 24047, Italy | |
Completed | Tel Aviv, 64239, Israel | |
Completed | Warszawa, 02-781, Poland | |
Completed | Berlin, 13125, Germany | |
Completed | Cuneo, 12100, Italy | |
Completed | Udine, 33100, Italy | |
Withdrawn | München, 80637, Germany | |
Withdrawn | Plantation, 33324, United States | |
Withdrawn | United Kingdom | |
Withdrawn | Rehovot, 7610001, Israel | |
Withdrawn | Jacksonville, 32209, United States | |
Withdrawn | Cardiff, CF14 2TL, United Kingdom | |
Withdrawn | Poland | |
Withdrawn | Philadelphia, 19106, United States | |
Withdrawn | München, 80336, Germany | |
Withdrawn | Perugia, 06122, Italy | |
Withdrawn | Louisville, 40202, United States | |
Withdrawn | Sutton, SM2 5PT, United Kingdom | |
Withdrawn | Columbus, 43213, United States | |
Withdrawn | Waterbury, 06708-2904, United States | |
Withdrawn | Columbus, 43235, United States |
Trial design
Trial Type
InterventionalIntervention Type
DrugTrial Purpose
TreatmentAllocation
Non-randomizedBlinding
Open LabelAssignment
Single Group AssignmentTrial Arms
1